Recombinant DNA has been explored since the late 1980s to increase residence times in one DNAencodngthebndingpomionofamonocionalantbodywasmCrgeiAwihhnahSg proach,mouse roducine Dheen. Human antibodies Ever since the discovery that monoclonal antibodies could be generated.scientists have targeted the creation of "fully"human products to reduce the side effects of humanised or chimeric antibodies.Two successful approaches have been identified:transgenic mice2 I and phage display. As of November 2016.thirteen of the nineteen "fully"human monoclonal antibody therapeutics on the market were derived from transgenic mice technology. Adopting organizations who market transgenic technology include: Meda Abgenix-which marketed the Xenomouse technology.Abgenix was acquired in April 2006 by .Regeneron's Veloclmmune) .Kymab-who market their Kymouset onal OmniM Ablexis.LLC- ouse platform ) Phage display c phae dis press variable antibody domains on filam ntous phage coat proteins(Phage lay an antibody libraries against diseased and non-diseased tis 19g be used maahrdgameaiomapaeonhlpesdSmvhndiae,hiammorydiscs In August 2006 the Pha tical Re companies hac ials Administration( by the d Dru Applications Diagnostic tests sue sections and Analytic and chemical uses Antibodies can also be used to purify their target compounds from mixtures,using the method of immunoprecipitation. Therapeutic treatment